ASLAN Pharmaceuticals Inc. (NASDAQ: ASLN) stock plunged by 35.23% in the current market trading session. ASLAN Pharmaceuticals is a clinical-stage immunology pharmaceutical business focusing on discovering novel medicines to improve patients’ lives.
ASLN stock’ Significant Development
ASLAN Pharmaceuticals revealed promising topline findings from their ASLAN004 for the cure of moderate-to-severe atopic dermatitis randomised, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 trial (AD). ASLAN004, a possible first-in-class monoclonal antibody targeting the IL-13 receptor, was well accepted in all dosages. The study’s findings demonstrate proof of concept and indicate ASLAN004’s potential as a differentiated, new therapy for Alzheimer’s disease.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
ASLAN released interim findings from three dosage escalation groups in March 2021, then continues to enrol and treat another 27 patients in an expansion cohort at the maximum dose (600mg). The results published today compare the outcomes of all 600mg patients with those of all placebo patients (n=39). The Intent to Treat (ITT) population (n=38) included patients from ten locations and has all patients dosed, with the exception of one patient who dropped out owing to COVID-19 limitations.
- At 8 weeks, the rate of decrease in EASI in the RITT population was 65 percent (n=16), relative to 27 percent (n=13) in the placebo group (p=0.0211).
- The average reduction from baseline in EASI at 8 weeks was 73 percent (n=19) in the 32 patients who effectively finished 29 days of treatment across all locations, as specified in the protocol as the effectiveness evaluable data set, compared to 44 percent (n=13) in the placebo group (p=0.0071).
- In both the treatment and placebo groups, the proportion of patients experiencing side effects and procedure related adverse events was equal. In the expansion cohort, there were no cases of conjunctivitis.
Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, stated,
They’re ecstatic to share such promising results for ASLAN004. The findings of the trial back up the belief that ASLAN004’s unique mechanism might be a new therapeutic choice for treatment with moderate-to-severe AD, with the ability to offer best-in-class effectiveness and safety. They’re excited to build on this excellent data set as they begin the Phase 2b study in the following weeks and look into monthly dosage schedules that may give patients with more convenience.